A comparative study on micelles, liposomes and solid lipid nanoparticles for paclitaxel delivery

Int J Pharm. 2023 Jan 25:631:122464. doi: 10.1016/j.ijpharm.2022.122464. Epub 2022 Dec 1.

Abstract

The purpose of this work was to compare the in vitro and in vivo characteristics of LDV-targeted lipid-based micelles, liposomes and solid lipid nanoparticles (SLN) to provide further insights into their therapeutic potential for clinical development. Micelles, liposomes and SLN were prepared using LDV peptide amphiphiles and palmitic acid-derived lipids using solvent evaporation, thin-film hydration and microfluidic mixing respectively. Nanocarriers were characterized for their physicochemical properties, paclitaxel loading efficiency, in vitro release behavior, stability in biological media as well as in vivo antitumor efficacy in melanoma xenograft model. TEM and DLS results confirmed the presence of paclitaxel-loaded nanosized micelles (6 to 12 nm), liposomes (123.31 ± 5.87 nm) and SLN (80.53 ± 5.37 nm). SLN demonstrated the slowest paclitaxel release rate and the highest stability in biological media compared to micelles and liposomes. Paclitaxel-loaded SLN demonstrated a statistically significant delay in tumor growth compared to mice treated with paclitaxel-loaded liposomes and paclitaxel-loaded micelles (p < 0.05). The results obtained in this study indicate the potential of SLN as drug delivery vehicles for anticancer therapy.

Keywords: LDV; Liposomes; Micelles; Paclitaxel; Solid Lipid Nanoparticles; Targeting.

MeSH terms

  • Animals
  • Cell Line, Tumor
  • Drug Carriers / chemistry
  • Humans
  • Liposomes*
  • Mice
  • Micelles
  • Nanoparticles* / chemistry
  • Paclitaxel
  • Particle Size

Substances

  • Lipid Nanoparticles
  • Liposomes
  • Paclitaxel
  • Micelles
  • Drug Carriers